Publication Month: Apr 2021 | Report Code: TIPRE00014239 | No. of Pages: 137 | Category: Medical Device | Status: Published
The growth of the market is attributed to the increasing prevalence of tuberculosis and government initiatives to promote tuberculosis detection. However, multidrug resistant tuberculosis (MDR-TB) is likely to hamper the growth of the Latent TB Detection market to a certain extent.
The disease disproportionally affects the poor, vulnerable, undernourished, and marginalized people worldwide. Evidence from various sources such as World Health Organization (WHO) and the United Nations (UN) shows that countries such as India and Indonesia in Asia Pacific are highly populated with patients suffering from TB. Thus, the government bodies in these countries are undertaking and adopting certain schemes and initiatives in containing the disease. For instance, the Indian National Strategic Plan (NSP) that aims for TB elimination has been established from 2017 to 2025; it institutes several patient support groups and protection measures along with the provision of free TB diagnostic tests and treatment for Indians. Furthermore, in March 2018, the Government of India, in association with the Directorate of General Health Services, introduced a new scheme known as “Nikshay Poshak Yojna” that included the provision of nutritional support for patients suffering with TB in India. Similarly, another scheme known as Direct Benefit Transfer (DBT) has been introduced for patients suffering from TB. This policy involves direct transfer of cash to the victim’s account intended for TB diagnostic tests, treatments, and medication costs.
Furthermore, western countries such as the US, the UK, and Canada are giving significant importance in combating TB by undertaking various funding programs. The US government is the largest donor of the Global Fund to fight AIDS, tuberculosis, and malaria. The US funding for global TB efforts was reported to be US$ 321 million in 2020. Thus, the financial and medical assistance from the governments for fighting the disease and promoting the diagnosis of TB is providing a lucrative scenario for the growth of the market.
Based on test, the latent TB detection market was segmented into Tuberculin Skin Test (TST) and Interferon Gamma Released Assay (IGRA). In 2019, the Interferon Gamma Released Assay (IGRA) segment accounted for the highest share in the market and is likely to retain its dominant share. Also, the similar segment is expected to witness fastest growth in the market owing to the accuracy obtained through these tests. The IGRA test has numerous advantages over the TST of not needing the patient to return for test result evaluation. Current IGRAs do not cross-react with most non-TB mycobacteria, including Bacille Calmette-Guerin (BCG) strains.
Based on end user, the latent TB detection market is segmented into hospitals, diagnostic centers, laboratory and others. The hospitals segment held the largest share of the market in 2019. Moreover, the same segment is estimated to register the highest CAGR in the market during the forecast period.
|Market Size Value in||US$ 1,131.82 Million in 2019|
|Market Size Value by||US$ 1,684.86 Million by 2027|
|Growth rate||CAGR of 5.2% from 2020-2027|
|No. of Pages||137|
|No. of Tables||51|
|No. of Charts & Figures||64|
|Historical data available||Yes|
|Segments covered||Test and Interferon Gamma Released Assay ); End User and Geography|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
The latent TB detection market players such as QIAGEN, BioMeriux S.A., F. Hoffmann La-Roche Ltd., BD, ARKRAY, Inc., Abbott, Serum Institute of India Pvt. Ltd, Oxford Immunotec Ltd, Lionex GmbH have been adopting several organic and inorganic strategies to enhance their revenue and market standings. For instance, in September 2020, Oxford Immunotec received approval from the FDA to allow use of the T-SPOT.TB test in two years of age and older. This will help in meeting the pediatric patients needs for TB management
The List of Companies - Latent TB Detection Market